CTI BioPharma Corporation, a biopharmaceutical company, has reported its financial results for the year ended 31 December 2018.
The company reported revenues for the year ended 31 December 2018 at USD26.3m compared to USD25.1m in the year-ago period.
The firm posted GAAP operating loss at USD32.9m for the year ended 31 December 2018 compared to GAAP operating loss of USD39.5m in 2017.
Net loss attributable to common stockholders for the twelve months ended 31 December 2018, was USD29.4m, or USD0.52 per share, compared to a net loss of USD45.0m, or USD1.24 per share, for the same period in 2017.
Operating loss for the year ended 31 December 2018 as compared to 2017 resulted primarily from the decrease in selling, general and administrative expenses.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva